Bacille Calmette-Guerin (BCG) vaccine for induction of remission in Crohn's disease

  • Protocol
  • Intervention

Authors

  • Wael El-Matary,

    Corresponding author
    1. Children's Hospital, Health Sciences Centre, Section of Pediatric Gastroenterology, Winnipeg, Manitoba, Canada
    2. King Saud University, Riyadh, Saudi Arabia
    3. University of Manitoba, Department of Pediatrics, Faculty of Medicine, Winnipeg, Manitoba, Canada
    • Wael El-Matary, Section of Pediatric Gastroenterology, Children's Hospital, Health Sciences Centre, AE-408, 840 Sherbrook St., Winnipeg, Manitoba, R3A 1S1, Canada. welmatary@yahoo.com. welmatary@hsc.mb.ca.

    Search for more papers by this author
  • Jason Yap,

    1. University of Alberta, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Dept. of Pediatrics, Stollery Children's Hospital, Faculty of Medicine, Edmonton, Alberta, Canada
    Search for more papers by this author
  • Susan Gilmour

    1. University of Alberta, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Dept. of Pediatrics, Stollery Children's Hospital, Faculty of Medicine, Edmonton, Alberta, Canada
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The primary objective is to systematically assess the efficacy and safety of BCG vaccine for induction of remission in active Crohn's disease.